Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill
Eli Lilly shares rose 3.7% to $1,058.18 Friday after Hims & Hers said it would halt sales of a compounded weight-loss pill following an FDA warning. U.S. regulators said they will crack down on mass-marketed, non-approved GLP-1 drugs. The FDA threatened legal action against violators and referred Hims to the Justice Department. Investors are watching for enforcement impact on obesity-drug pricing.